Ofatumumab for High-Risk Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 31, 2011

Primary Completion Date

March 28, 2023

Study Completion Date

March 28, 2023

Conditions

Chronic Lymphocytic Leukemia

Interventions

DRUG

Ofatumumab

Loading first dose 300 mg by vein on Day 1 of Cycle 1; and full dose 1000 mg over 4 hours 1 time each week for 7 additional weekly doses (8 doses).

Trial Locations (1)

University of Texas MD Anderson Cancer Center, Houston